Global Non-GMP Development Market Outlook and Growth Opportunities 2026
Description
The global Non-GMP Development market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Asia Pacific market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Non-GMP Development market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Non-GMP Development market include Almac, GTP Technology, Alfa Aesar, Sundia-Manufacturing, J-STAR Research Inc., Lonza, AmbioPharm, Velesco and CordenPharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Non-GMP Development market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Non-GMP Development and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Non-GMP Development revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-GMP Development market.
Non-GMP Development Segment by Company
Almac
GTP Technology
Alfa Aesar
Sundia-Manufacturing
J-STAR Research Inc.
Lonza
AmbioPharm
Velesco
CordenPharma
Piramal Pharma Solutions
Norwich
Aurigene Pharmaceutical Services
Actylis
CARBOGEN AMCIS
GTP Bioways
Symeres
Quotient Sciences
Non-GMP Development Segment by Type
Research Grade
Animal Free Grade
Non-GMP Development Segment by Application
Commercial & Academic
Clinical
Others
Non-GMP Development Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Non-GMP Development status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Non-GMP Development key companies, revenue, market share, and recent developments.
3. To split the Non-GMP Development breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Non-GMP Development market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Non-GMP Development significant trends, drivers, influence factors in global and regions.
6. To analyze Non-GMP Development competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-GMP Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-GMP Development and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-GMP Development.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-GMP Development industry.
Chapter 3: Detailed analysis of Non-GMP Development company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Non-GMP Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Non-GMP Development in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
The North America market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Asia Pacific market for Non-GMP Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Non-GMP Development market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Non-GMP Development market include Almac, GTP Technology, Alfa Aesar, Sundia-Manufacturing, J-STAR Research Inc., Lonza, AmbioPharm, Velesco and CordenPharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Non-GMP Development market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Non-GMP Development and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Non-GMP Development revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-GMP Development market.
Non-GMP Development Segment by Company
Almac
GTP Technology
Alfa Aesar
Sundia-Manufacturing
J-STAR Research Inc.
Lonza
AmbioPharm
Velesco
CordenPharma
Piramal Pharma Solutions
Norwich
Aurigene Pharmaceutical Services
Actylis
CARBOGEN AMCIS
GTP Bioways
Symeres
Quotient Sciences
Non-GMP Development Segment by Type
Research Grade
Animal Free Grade
Non-GMP Development Segment by Application
Commercial & Academic
Clinical
Others
Non-GMP Development Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Non-GMP Development status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Non-GMP Development key companies, revenue, market share, and recent developments.
3. To split the Non-GMP Development breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Non-GMP Development market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Non-GMP Development significant trends, drivers, influence factors in global and regions.
6. To analyze Non-GMP Development competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-GMP Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-GMP Development and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-GMP Development.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-GMP Development industry.
Chapter 3: Detailed analysis of Non-GMP Development company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Non-GMP Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Non-GMP Development in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
204 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Non-GMP Development Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Non-GMP Development Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Non-GMP Development Market Dynamics
- 2.1 Non-GMP Development Industry Trends
- 2.2 Non-GMP Development Industry Drivers
- 2.3 Non-GMP Development Industry Opportunities and Challenges
- 2.4 Non-GMP Development Industry Restraints
- 3 Non-GMP Development Market by Company
- 3.1 Global Non-GMP Development Company Revenue Ranking in 2025
- 3.2 Global Non-GMP Development Revenue by Company (2021-2026)
- 3.3 Global Non-GMP Development Company Ranking (2024-2026)
- 3.4 Global Non-GMP Development Company Manufacturing Base and Headquarters
- 3.5 Global Non-GMP Development Company Product Type and Application
- 3.6 Global Non-GMP Development Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Non-GMP Development Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Non-GMP Development Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Non-GMP Development Market by Type
- 4.1 Non-GMP Development Type Introduction
- 4.1.1 Research Grade
- 4.1.2 Animal Free Grade
- 4.2 Global Non-GMP Development Sales Value by Type
- 4.2.1 Global Non-GMP Development Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Non-GMP Development Sales Value by Type (2021-2032)
- 4.2.3 Global Non-GMP Development Sales Value Share by Type (2021-2032)
- 5 Non-GMP Development Market by Application
- 5.1 Non-GMP Development Application Introduction
- 5.1.1 Commercial & Academic
- 5.1.2 Clinical
- 5.1.3 Others
- 5.2 Global Non-GMP Development Sales Value by Application
- 5.2.1 Global Non-GMP Development Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Non-GMP Development Sales Value by Application (2021-2032)
- 5.2.3 Global Non-GMP Development Sales Value Share by Application (2021-2032)
- 6 Non-GMP Development Regional Value Analysis
- 6.1 Global Non-GMP Development Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Non-GMP Development Sales Value by Region (2021-2032)
- 6.2.1 Global Non-GMP Development Sales Value by Region: 2021-2026
- 6.2.2 Global Non-GMP Development Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Non-GMP Development Sales Value (2021-2032)
- 6.3.2 North America Non-GMP Development Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Non-GMP Development Sales Value (2021-2032)
- 6.4.2 Europe Non-GMP Development Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Non-GMP Development Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Non-GMP Development Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Non-GMP Development Sales Value (2021-2032)
- 6.6.2 South America Non-GMP Development Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Non-GMP Development Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Non-GMP Development Sales Value Share by Country, 2025 VS 2032
- 7 Non-GMP Development Country-level Value Analysis
- 7.1 Global Non-GMP Development Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Non-GMP Development Sales Value by Country (2021-2032)
- 7.2.1 Global Non-GMP Development Sales Value by Country (2021-2026)
- 7.2.2 Global Non-GMP Development Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.7.2 France Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.14.2 China Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.17.2 India Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Non-GMP Development Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Non-GMP Development Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Non-GMP Development Sales Value Share by Application, 2025 VS 2032
- 8 Company Profiles
- 8.1 Almac
- 8.1.1 Almac Company Information
- 8.1.2 Almac Business Overview
- 8.1.3 Almac Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.1.4 Almac Non-GMP Development Product Portfolio
- 8.1.5 Almac Recent Developments
- 8.2 GTP Technology
- 8.2.1 GTP Technology Company Information
- 8.2.2 GTP Technology Business Overview
- 8.2.3 GTP Technology Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.2.4 GTP Technology Non-GMP Development Product Portfolio
- 8.2.5 GTP Technology Recent Developments
- 8.3 Alfa Aesar
- 8.3.1 Alfa Aesar Company Information
- 8.3.2 Alfa Aesar Business Overview
- 8.3.3 Alfa Aesar Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.3.4 Alfa Aesar Non-GMP Development Product Portfolio
- 8.3.5 Alfa Aesar Recent Developments
- 8.4 Sundia-Manufacturing
- 8.4.1 Sundia-Manufacturing Company Information
- 8.4.2 Sundia-Manufacturing Business Overview
- 8.4.3 Sundia-Manufacturing Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.4.4 Sundia-Manufacturing Non-GMP Development Product Portfolio
- 8.4.5 Sundia-Manufacturing Recent Developments
- 8.5 J-STAR Research Inc.
- 8.5.1 J-STAR Research Inc. Company Information
- 8.5.2 J-STAR Research Inc. Business Overview
- 8.5.3 J-STAR Research Inc. Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.5.4 J-STAR Research Inc. Non-GMP Development Product Portfolio
- 8.5.5 J-STAR Research Inc. Recent Developments
- 8.6 Lonza
- 8.6.1 Lonza Company Information
- 8.6.2 Lonza Business Overview
- 8.6.3 Lonza Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.6.4 Lonza Non-GMP Development Product Portfolio
- 8.6.5 Lonza Recent Developments
- 8.7 AmbioPharm
- 8.7.1 AmbioPharm Company Information
- 8.7.2 AmbioPharm Business Overview
- 8.7.3 AmbioPharm Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.7.4 AmbioPharm Non-GMP Development Product Portfolio
- 8.7.5 AmbioPharm Recent Developments
- 8.8 Velesco
- 8.8.1 Velesco Company Information
- 8.8.2 Velesco Business Overview
- 8.8.3 Velesco Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.8.4 Velesco Non-GMP Development Product Portfolio
- 8.8.5 Velesco Recent Developments
- 8.9 CordenPharma
- 8.9.1 CordenPharma Company Information
- 8.9.2 CordenPharma Business Overview
- 8.9.3 CordenPharma Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.9.4 CordenPharma Non-GMP Development Product Portfolio
- 8.9.5 CordenPharma Recent Developments
- 8.10 Piramal Pharma Solutions
- 8.10.1 Piramal Pharma Solutions Company Information
- 8.10.2 Piramal Pharma Solutions Business Overview
- 8.10.3 Piramal Pharma Solutions Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.10.4 Piramal Pharma Solutions Non-GMP Development Product Portfolio
- 8.10.5 Piramal Pharma Solutions Recent Developments
- 8.11 Norwich
- 8.11.1 Norwich Company Information
- 8.11.2 Norwich Business Overview
- 8.11.3 Norwich Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.11.4 Norwich Non-GMP Development Product Portfolio
- 8.11.5 Norwich Recent Developments
- 8.12 Aurigene Pharmaceutical Services
- 8.12.1 Aurigene Pharmaceutical Services Company Information
- 8.12.2 Aurigene Pharmaceutical Services Business Overview
- 8.12.3 Aurigene Pharmaceutical Services Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.12.4 Aurigene Pharmaceutical Services Non-GMP Development Product Portfolio
- 8.12.5 Aurigene Pharmaceutical Services Recent Developments
- 8.13 Actylis
- 8.13.1 Actylis Company Information
- 8.13.2 Actylis Business Overview
- 8.13.3 Actylis Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.13.4 Actylis Non-GMP Development Product Portfolio
- 8.13.5 Actylis Recent Developments
- 8.14 CARBOGEN AMCIS
- 8.14.1 CARBOGEN AMCIS Company Information
- 8.14.2 CARBOGEN AMCIS Business Overview
- 8.14.3 CARBOGEN AMCIS Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.14.4 CARBOGEN AMCIS Non-GMP Development Product Portfolio
- 8.14.5 CARBOGEN AMCIS Recent Developments
- 8.15 GTP Bioways
- 8.15.1 GTP Bioways Company Information
- 8.15.2 GTP Bioways Business Overview
- 8.15.3 GTP Bioways Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.15.4 GTP Bioways Non-GMP Development Product Portfolio
- 8.15.5 GTP Bioways Recent Developments
- 8.16 Symeres
- 8.16.1 Symeres Company Information
- 8.16.2 Symeres Business Overview
- 8.16.3 Symeres Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.16.4 Symeres Non-GMP Development Product Portfolio
- 8.16.5 Symeres Recent Developments
- 8.17 Quotient Sciences
- 8.17.1 Quotient Sciences Company Information
- 8.17.2 Quotient Sciences Business Overview
- 8.17.3 Quotient Sciences Non-GMP Development Revenue and Gross Margin (2021-2026)
- 8.17.4 Quotient Sciences Non-GMP Development Product Portfolio
- 8.17.5 Quotient Sciences Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


